T he patient is a 74-year-old woman with a history of paroxysmal atrial fibrillation, hypertension, and dyslipidemia, who initially presented to an outside hospital in 2009 with a transient ischemic attack. Evaluation identified a patent foramen ovale; a percutaneous closure of the patent foramen ovale was performed using a StarFLEX atrial septal occluder device.
In 2010, the patient had a deep venous thrombosis in the setting of several weeks of bed rest following a spinal procedure treated with 3 months of therapeutic anticoagulation with warfarin. Hematologic evaluation did not reveal evidence of hypercoagulable disorder, although the patient was noted to be heterozygous for Factor V Leiden. In 2011, the patient had a routine follow-up echocardiogram that showed preserved systolic function without evidence of intracardiac mass or residual shunt.
In October 2014, the patient developed sudden onset chest pain and was found to have a non-ST-segment-elevation myocardial infarction. An echocardiogram showed preserved systolic function with normal regional wall motion; a 2×1.8 cm sessile mass attached to the septal occluder device was identified in the left atrium. Anticoagulation with warfarin was initiated, and the patient was discharged. A transesophageal echocardiogram in January 2015 showed persistence of the thrombus despite stable therapeutic anticoagulation. The patient then presented in February 2015 with acute onset headache, dizziness, and gait unsteadiness that self-resolved within 1 hour concerning for transient ischemic attack. An echocardiogram showed enlargement of the left atrial thrombus despite therapeutic anticoagulation. The patient was converted to enoxaparin and referred for surgical resection of the atrial septal occluder device. Of note, on further history, the patient reported a suspected nickel allergy, although no patch testing had been performed.
Preoperative coronary angiography showed no significant coronary artery disease. The next day, the patient experienced transient visual field deficits. Head computed tomography did not reveal an acute intracranial process. Anticoagulation converted from enoxaparin to continuous heparin infusion.
The patient underwent urgent resection of the septal occluder device with the attached thrombus and bovine patch reconconstruction of the interatrial septum and dome of the left atrium (Figure) . Postoperatively, the patient remained in a junctional bradycardia requiring implantation of a dual chamber permanent pacemaker.
Discussion
Atrial thrombus formation on atrial septal closure devices is a recognized postprocedural complication. However, the development of thrombus 6 years after device implantation is a rarely reported complication.
In 1 large series of patients undergoing percutaneous patent foramen ovale and atrial septal defect closure, Krumsdorf et al 1 described the incidence of thrombus formation based on transesophgeal echocardiography at 1 and 6 months. Overall thrombus incidence was 2%; incidence was 1.2% in patients with atrial septal defect closures and 2.5% in patients with patent foramen ovale closure. Of the 296 patients with devices using a star-shaped metallic arm design, including the StarFLEX device, 14 (4.7%) developed thrombus. The difference between the thrombus incidence of these devices and the Amplatzer septal occluder device (1, 0.3%) was statistically significant. Of the 20 patients developing thrombus, 3 required surgical resection; 2 of these patients had StarFLEX devices. 1 Development of thrombus >1 year after implantation is a rarely reported complication of interatrial septal occluder device implantation. Gaul et al 2 reported a case in which a patient developed a left atrial thrombus, diagnosed after cerebrovascular accident, 5.7 years after the implantation of a Buttoned interatrial septal occluder. Narayan et al 3 reported another case of a patient developing left atrial thrombus, identified after transient ischemic attack, 3 years after implantation of a CardioSEAL interatrial septal occluder.
Our patient also reported a suspected nickel allergy, which has been described as a potential risk factor for adverse events in the use of implantable nickel-containing devices, such as interatrial septal occluder devices. This type IV hypersensitivity reaction may contribute to these complications through an immune-mediated T-cell driven process. Kim et al recently described a series of patients undergoing atrial septal defect closure using the nickel-containing Amplatzer device including 5 with nickel allergy confirmed by patch testing; migraine was the only adverse event noted more frequently in the nickel-allergic group. Atrial thrombus was not reported in any patients, including 33 nonallergic patients. 4 However, this study has limited generalizability, particularly to other types of devices with different structures, nickel content, and nickel exposure. In this patient, the surgical specimen was noted to have significant inflammation and hypertrophied scar on visual inspection raising concern that a chronic inflammatory process may have played a role. Although the patient does have a history of deep venous thrombosis, it was provoked and hematologic evaluation did not reveal a hypercoagulability disorder. Factor V Leiden heterogeneity is extremely unlikely to be explanatory in isolation but may have further contributed to thrombus formation in the setting of an inflammatory, incompletely endothelialized surface.
Here, we describe a case of late presentation left atrial thrombus related to interatrial septal occluder device. As percutaneous atrial septal defect and patent foramen ovale closure becomes increasingly common, this complication is an important consideration in the long-term management of these patients. Although modern closure devices have reported low thrombus rates at ≤1 year of follow-up, long-term data are more limited. As such, it is an important consideration for cardiologists and clinicians managing these patients, particularly in those patients presenting with possible embolic phenomenon. 
